Sodium channel blocker with potent anticonvulsant activity; potential for novel treatment for Schizophrenia. CNV 1014802 (GSK2) was tested in clinical trials for treatment of trigeminal neuralgia, and shows selectivity for the Nav1.7 subtype over the other subtypes tested (Nav1.1, Nav1.2, Nav1.3, Nav1.5, Nav1.6 and TTX-R), for both the resting and depolarized states.
The parent molecule of CNV 1014802 (Axon 1899) is available as well.
KEYWORDS: CNV 1014802 hydrochloride | supplier | Na+ channel blocker | GSK 1014802 HCl | GSK2 HCl | Raxatrigine HCl | BIIB 074 HCl | Vixotrigine HCl | CNV1014802 hydrochloride | CNV-1014802 hydrochloride | GSK1014802 HCl | GSK-1014802 HCl | GSK 2 HCl | GSK-2 HCl | BIIB074 HCl | BIIB-074 HCl | CAS [934240-31-0] | [934240-30-9] | Sodium | Nav1.7 | Nav1.2 | Nav1.6 | Nav1.3 | Blocker | Ion Channels | anticonvulsant | Schizophrenia | trigeminal neuralgia | neuropathic | pain